Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS8580-TPS8580
◽
2017 ◽
Vol 12
(6)
◽
pp. 983-992
◽
Keyword(s):
Keyword(s):